Anavex Life Sciences Corp.
(NASDAQ : AVXL)

( )
AVXL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.04%108.241.1%$605.41m
GILDGilead Sciences, Inc.
-2.93%74.340.9%$540.78m
AMGNAmgen Inc.
-1.39%174.921.1%$476.57m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%383.122.7%$338.65m
BIIBBiogen Inc.
-2.17%323.551.2%$316.85m
ALXNAlexion Pharmaceuticals, Inc.
-0.40%113.091.9%$255.42m
BLUEBluebird Bio, Inc.
-0.30%184.3516.1%$198.90m
VRTXVertex Pharmaceuticals Incorporated
-1.57%142.531.9%$197.41m
ILMNIllumina, Inc.
-1.73%210.853.5%$160.91m
ALNYAlnylam Pharmaceuticals, Inc
-0.96%123.6610.0%$160.42m
NKTRNektar Therapeutics
-2.79%55.056.1%$153.38m
AAgilent Technologies, Inc.
-0.26%66.511.5%$152.00m
INCYIncyte Corporation
-2.17%95.972.5%$129.88m
BMRNBioMarin Pharmaceutical Inc.
-0.15%88.534.4%$100.67m
JUNOJuno Therapeutics, Inc.
-6.83%44.1713.5%$94.92m

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.